Floxacin

Información principal

  • Denominación comercial:
  • Floxacin Inyectable Serveco
  • Usar para:
  • Animales
  • Tipo de medicina:
  • medicamento alopático

Documentos

Localización

  • Disponible en:
  • Floxacin Inyectable Serveco
    Venezuela
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • última actualización:
  • 03-09-2018

Prospecto

acin Inyectable Serveco

COMPOSICIÓN:

Enrofloxacina.

INDICACIONES:

Tratamiento de las enfermedades causadas por gérmenes Gram positivos y Gram negativos,

Mycoplasmosis y Rickettsias en Aves, Bovinos y Porcinos.

DOSIFICACIÓN:

Bovinos y Porcinos 0,5 ml/10 Kpv. diariamente por 3 días. Aves vía subcutánea 2,5 ml/kpv, por 3 días.

Prolongar hasta 5 días

ADMINISTRACIÓN:

Intramuscular Bovinos y Porcinos, subcutánea en Aves.

FABRICANTE:

Laboratorios Serveco

USADO EN ESPECIES:

Aves

Bovinos

Porcinos

22-10-2018

Promise Pharmacy Issues Voluntary Nationwide Recall of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% Sterile Due to Small Particulate Floating in the Solution

Promise Pharmacy Issues Voluntary Nationwide Recall of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% Sterile Due to Small Particulate Floating in the Solution

Promise Pharmacy is voluntarily recalling one lot of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% sterile, 3ml vials, to the patient consumer level. The product has been found to have unidentified small particulate floating in the solution.

FDA - U.S. Food and Drug Administration

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

3-2-2014

Danish Pharmacovigilance Update 28 November 2013

Danish Pharmacovigilance Update 28 November 2013

In this issue of Danish Pharmacovigilance Update: Ciprofloxacin and the risk of tendon disorders, risk of blood clots from the use of the cancer medicine ponatinib and reporting of adverse reactions to the Danish Health and Medicines Authority.

Danish Medicines Agency

13-6-2018

Veraflox (Bayer Animal Health GmbH)

Veraflox (Bayer Animal Health GmbH)

Veraflox (Active substance: Pradofloxacin) - Centralised - Yearly update - Commission Decision (2018)3834 of Wed, 13 Jun 2018

Europe -DG Health and Food Safety

11-6-2018

Quinsair (Chiesi Farmaceutici S.p.A.)

Quinsair (Chiesi Farmaceutici S.p.A.)

Quinsair (Active substance: levofloxacin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3756 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2789/T/16

Europe -DG Health and Food Safety